10X Genomics Inc reports results for the quarter ended March 31 - Earnings Summary

10x Genomics

09/05/2025 24:01

10X Genomics Inc TXG.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -50 cents.  The mean expectation of nineteen analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -65 cents to -31 cents per share.

Revenue rose 9.8% to $154.88 million from a year ago; analysts expected $132.45 million.

10X Genomics Inc's reported EPS for the quarter was a loss of 28 cents​.

The company reported a quarterly loss of $34.36 million.

10X Genomics Inc shares had fallen by 4.8% this quarter and lost 42.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 19.8% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy," 10 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for 10X Genomics Inc is $14.50

This summary was machine generated from LSEG data May 8 at 11:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.47
-0.36
Beat
Dec. 31 2024
-0.29
-0.40
Missed
Sep. 30 2024
-0.34
-0.30
Beat
Jun. 30 2024
-0.48
-0.32
Beat